You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Mallinckrodt
McKinsey
McKesson
Moodys

Last Updated: February 20, 2020

DrugPatentWatch Database Preview

Claims for Patent: 8,404,717


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,404,717
Title:Methods of treating myelodysplastic syndromes using lenalidomide
Abstract: Methods of treating, preventing and/or managing myelodysplastic syndromes are disclosed. Specific methods encompass the administrations of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin-2,6-dione in combination with 5-azacytidine.
Inventor(s): Zeldis; Jerome B. (Princeton, NJ)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:13/070,761
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,404,717
Patent Claims: 1. A method of treating a patient having transfusion dependent anemia due to low to intermediate-1-risk myelodysplastic syndrome, which comprises administering to said patient in need thereof about 5 to about 25 mg per day of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione having the formula: ##STR00010## or a pharmaceutically acceptable salt, solvate or stereoisomer thereof.

2. The method of claim 1, wherein the compound is administered in the amount of 5 mg per day.

3. The method of claim 2, wherein the compound is administered orally in an amount of 5 mg as a capsule per day.

4. The method of claim 1, wherein the compound is administered in the amount of 10 mg per day.

5. The method of claim 4, wherein the compound is administered orally in an amount of 10 mg as a capsule per day.

6. The method of claim 1, wherein the compound is administered in the amount of 15 mg per day.

7. The method of claim 6, wherein the compound is administered orally in an amount of 15 mg as a capsule per day.

8. The method of claim 1, wherein the compound is administered in the amount of 25 mg per day.

9. The method of claim 8, wherein the compound is administered orally in an amount of 25 mg as a capsule per day.

10. The method of claim 3, 5, 7 or 9, wherein the compound 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione is as a free base.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Boehringer Ingelheim
Dow
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.